Table 1.
Clinicopathological data of 157 lung cancer patients
| RET | |||
|---|---|---|---|
| Factors | No. of patients (N = 157) | T/N ratio of RET/β-actin mRNA levels | P-value |
| Mean age (years) | 66.7 ± 9.0 | ||
| Stage | |||
| I | 105 (66.9%) | 8.534 ± 30.678 | NS |
| II | 23 (14.6%) | 6.981 ± 12.707 | |
| III–IV | 29 (18.5%) | 11.603 ± 40.194 | |
| Tumor status | |||
| T1 | 73 (46.5%) | 11.044 ± 39.731 | NS |
| T2 | 62 (39.5%) | 7.242 ± 21.568 | |
| T3 | 7 (4.5%) | 10.454 ± 16.874 | |
| T4 | 15 (9.6%) | 4.318 ± 13.079 | |
| Lymph node metastasis | |||
| N0 | 116 (73.9%) | 8.587 ± 29.636 | NS |
| N1 | 23 (14.6%) | 5.414 ± 10.982 | |
| N2 | 18 (11.5%) | 15.690 ± 49.890 | |
| Pathological subtype | |||
| Adenocarcinoma | 127 (80.9%) | 10.465 ± 33.907 | 0.2652 |
| Others | 30 (19.1%) | 2.137 ± 3.865 | |
| KIF5B/RET rearrangement | |||
| Positive | 3 (1.9%) | 161.76 ± 123.488 | 0.044 |
| Negative | 154 (91.8%) | 5.901 ± 17.148 | |
| Smoking | |||
| BI = 0 | 52 (33.1%) | 14.047 ± 45.428 | 0.6693 |
| BI > 0 | 105 (66.9%) | 6.312 ± 19.525 | |
| Age | |||
| 65≤ | 80 (51.0%) | 10.318 ± 3.579 | 0.9147 |
| >65 | 77 (49.0%) | 7.385 ± 3.350 | |
| Gender | |||
| Male | 104 (66.2%) | 6.473 ± 19.581 | 0.7636 |
| Female | 53 (33.8%) | 13.584 ± 45.087 | |
T/N, tumor/normal; NS, not significant; BI, Brinkman index.